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Long-Term Clinical Outcomes
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Objectives This study examined the clinical outcomes at 5 years in RAVEL (A Randomized Comparison of a Sirolimus-Eluting
Stent With a Standard Stent for Coronary Revascularization), the first controlled trial of drug-eluting stents.
Background The 6-month rate of angiographic coronary restenosis has been markedly lowered by sirolimus-eluting stents
(SES). The long-term performance of drug-eluting stents, however, is under close scrutiny.
Methods The trial included 238 patients (mean age 60.7 10.4 years, 76% men) with a single, de novo native coronary artery
lesion, randomly assigned to treatment with SES versus bare-metal stents (BMS). Rates of major adverse cardiac
events (MACE), defined as all-cause mortality, myocardial infarction, and percutaneous or surgical revascularization
up to 5 years of follow-up, and rates of stent thrombosis were compared between the 2 treatment groups.
Results Complete datasets were available in 92.5% of patients treated with SES and 89.1% of patients assigned to
BMS. The 1-, 3-, and 5-year rates of survival free from target lesion revascularization (TLR) were, respectively,
99.2%, 93.8%, and 89.7% in the SES group versus 75.9%, 75.0%, and 74.0% in the control group (p  0.001;
log-rank). Rates of all MACE at 5 years were 25.8% in patients treated with SES versus 35.2% in patients as-
signed to BMS (p  0.03; log-rank). Rates of stent thrombosis, per protocol or by the Academic Research Con-
sortium definitions, were similar in both groups.
Conclusions The 5-year rate of TLR associated with SES was significantly lower than that with BMS. There was no apparent
adverse effect associated with the use of SES, although the trial was not powered to examine uncommon
complications. (J Am Coll Cardiol 2007;50:1299–304) © 2007 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.06.029c
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rhe RAVEL (A Randomized Comparison of a Sirolimus-
luting Stent With a Standard Stent for Coronary Revas-
ularization) study was the first of several randomized
linical trials that demonstrated the superior efficacy of
oronary sirolimus-eluting stents (SES) in the prevention of
eointimal proliferation and restenosis (1–4). The number
f patients enrolled in the trial was calculated in order to
rom the *Institut Cardiovasculaire Paris Sud, Massy, France; †Erasmus Medical
enter, Rotterdam, the Netherlands; ‡Clinique Beauregard, Marseille, France;
Albert-Ludwigs-Universitätskliniken, Kardiologie, Freiburg, Germany; Cardialy-
is, Rotterdam, the Netherlands; ¶Cordis Clinical Research, Waterloo, Belgium;
Cordis Clinical Research, Warren, New Jersey; **Harvard Clinical Research Insti-
ute, Boston, Massachusetts; and the ††Instituto Dante Pazzanese, Sao Paulo, Brazil.
his study was sponsored by Cordis Corporation (a Johnson & Johnson Company),
linical Research Europe, Belgium, and Warren, New Jersey.(
Manuscript received April 5, 2007; revised manuscript received June 11, 2007,
ccepted June 18, 2007.ompare the efficacy of SES versus that of conventional
are-metal stents (BMS) on angiographic end points, with
primary trial end point of in-stent late loss at 6 months of
ollow-up. This pioneering study was also initially planned
or a clinical follow-up limited to 1 year. However, it was
ubsequently extended to 5 years. The 6-month angiographic
nd 3-year clinical results (1,5) and a detailed intravascular
ltrasound-based study in a subset of 95 patients (6) have
een published. This report describes the final clinical
utcomes observed in RAVEL, up to 5 years of follow-up.
ethods
atient selection. The design and detailed methods of this
andomized, double-blind clinical trial have been reported
1,5). In brief, the 238 patients randomly assigned to SES
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ble angina pectoris, or silent
ischemia due to a single, 51% to
99% diameter stenosis de novo
coronary lesion, which could be
treated with a single 18-mm
stent, in a vessel between 2.5 and
3.5 mm in diameter. Major ex-
clusion criteria included evolving
myocardial infarction (MI), a
50% stenosis in an unprotected
left main coronary artery, an os-
tial target lesion, a calcified lesion
that could not be successfully
predilated with an angioplasty
balloon, or an angiographically
visible thrombus within the tar-
get lesion, a left ventricular ejec-
ion fraction 30%, a serum creatinine concentration 3.0
g/dl, and any contraindication to coronary artery bypass
raft surgery. Direct stenting was not allowed. The study
as reviewed and approved by each participating institu-
ion’s ethical review committee, and all patients provided
ritten informed consent before enrollment.
tudy procedures. After successful predilatation of the
arget lesion, patients were randomly assigned 1:1 in a
ouble-blind fashion to a BMS, versus an SES. Direct
tenting was not allowed. Postdilatation was performed as
ecessary. Procedural success was defined as attainment of a
30% vessel diameter stenosis and freedom from in-hospital
ajor adverse cardiac events (MACE) after implantation of
he assigned study device. Postprocedural dual antiplatelet
herapy consisted of aspirin 325 mg daily, indefinitely, and
ither clopidogrel 75 mg daily or ticlopidine 250 mg twice
aily, for 8 weeks.
atient follow-up. Patients returned for yearly follow-up
valuations to monitor the possible interim development
f angina or MACE. Follow-up angiography with quan-
itative coronary angiography (QCA) was systematically
erformed at 180  30 days as described previously (1).
he decision to perform further target lesion revascular-
zation (TLR) target or vessel revascularization (TVR)
fter the 6-month angiographic follow-up was left to the
nvestigator’s discretion, by protocol design.
tudy end points and definitions. The main study ob-
ective was to assess the effectiveness of the CYPHER
Cordis Corp., Johnson & Johnson, Miami Lakes, Flor-
da) SES in reducing angiographic in-stent late loss in de
ovo native coronary lesions as compared with the Bx
ELOCITY (Cordis Corp.) balloon-expandable BMS of
dentical design and appearance. The primary end point
f the study was angiographic, in-stent late loss at 6 months
f follow-up, measured by QCA. Secondary end points of
he trial included: 1) postprocedural, in-stent mean percent
iameter stenosis measured by QCA; 2) in-target vessel
Abbreviations
and Acronyms
ARC  Academic Research
Consortium
BMS  bare-metal stent(s)
MACE  major adverse
cardiac events
MI  myocardial infarction
QCA  quantitative
coronary angiography
SES  sirolimus-eluting
stent(s)
TLR  target lesion
revascularization
TVR  target vessel
revascularizationegment and in-stent minimum luminal diameter at 6 ionths; 3) MACE; and 4) TVR, up to 5 years of follow-up.
ajor adverse cardiac events were a composite end point
ncluding: 1) death from all causes; 2) Q-wave or non–Q-
ave MI; and 3) surgical or percutaneous TLR.
tent thrombosis. PER-PROTOCOL DEFINITIONS. In March
000, when the study protocol was developed, stent thrombo-
is was prospectively defined as a composite 30-day end point
ncluding death, Q-wave MI, and abrupt vessel closure
equiring revascularization. It was defined as acute when
ccurring within the first 24 h after stent implantation, and
ubacute when occurring between 24 h and 30 days after
he index procedure. In 2002, when its importance had
ecome apparent, late stent thrombosis was defined post
oc by the clinical events committee, with the endorse-
ent of the steering committee, as all target-vessel-
elated MI with angiographic evidence of vessel occlusion
ccurring past 30 days after the index procedure, in
bsence of interim TLR.
CADEMIC RESEARCH CONSORTIUM (ARC) DEFINITIONS. In
006, the ARC redefined the criteria for stent thrombosis
pplicable to clinical trials (7). The ARC definitions con-
ider the timing and probability of occurrence of stent
hrombosis. With respect to timing, stent thrombosis is
efined as acute if it occurred between 0 and 24 h, subacute
etween 25 h and 30 days, late between 31 days and 1 year,
nd very late beyond 1 year after stent implantation. With
espect to probability, stent thrombosis is defined as definite,
robable, or possible.
Definite stent thrombosis is considered to have oc-
urred on the basis of either angiographic or pathological
vidence.
NGIOGRAPHIC CONFIRMATION OF STENT THROMBOSIS.
tent thrombosis has been confirmed angiographically if:
hrombolysis In Myocardial Infarction flow is: a) grade 0
ith occlusion originating in the stent or in the segment, 5
m proximal or distal to the stent, in presence of a
hrombus, or b) grade 1, 2, or 3 originating in the stent
r in the segment, 5 mm proximal or distal to the stent,
n presence of a thrombus, and at least 1 of the following
riteria has been fulfilled within a 48-h time window: a)
cute onset of typical chest pain at rest, lasting 20 min,
) new electrocardiographic changes consistent with
cute myocardial ischemia, and c) typical rise and fall in
ardiac biomarkers. The incidental angiographic docu-
entation of stent occlusion in the absence of clinical
igns or symptoms (silent occlusion) is not considered a
onfirmed stent thrombosis.
ATHOLOGICAL CONFIRMATION OF STENT THROMBOSIS.
tent thrombosis is confirmed when there is presence of
ecent thrombus within the stent, found at autopsy or
y examination of tissue retrieved at the time of
hrombectomy.
Probable stent thrombosis is considered to have occurredn case of: 1) unexplained death within the first 30 days after
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October 2, 2007:1299–304 5-Year Outcomes in RAVELtent implantation; or 2) MI in the territory of the im-
lanted stent, in absence of another obvious cause, without
ngiographic confirmation of stent thrombosis and regard-
ess of its timing after the index procedure.
Possible stent thrombosis is considered to have occurred as
cause of any unexplained death past 30 days after intra-
oronary stenting, until the end of trial follow-up.
Unlike the RAVEL protocol definition, ARC includes
vents consistent with stent thrombosis that occur after
epeat TLR.
ata management and study oversight. The angiographic
nd clinical data were collected by monitors independent of
he sponsor and were transferred to Cardialysis (Rotterdam,
he Netherlands), an independent contract research organi-
ation. Cardialysis managed and analyzed the data, and
erformed the angiographic core laboratory analyses.
During the course of the study, end points were adjudi-
ated by an independent clinical events committee, man-
ged by Cardialysis. In addition, a data safety monitoring
oard not affiliated with the study sponsor reviewed the data
nd identified potential safety issues related to the conduct
f the study. Finally, in September 2006, after the ARC
efinitions of stent thrombosis had been formulated, ad-
erse clinical events were readjudicated retrospectively by
he Harvard Clinical Research Institute, Boston, Massachu-
etts, from the database transferred by Cardialysis.
tatistical analyses. For the primary (angiographic) end
oint, it was estimated that a sample size of 95 in each group
ad an 87% power to detect a difference in means of
.25 mm (the difference between a BMS late loss mean of
.80 mm and a SES late loss mean of 0.55 mm) assuming
hat the common standard deviation is 0.55, using a 2-group
test with a 0.05 1-sided significance level. The sample size
as increased to 110 in each group to account for noncom-
liance to the 6-month angiographic follow-up.
All analyses were based on the intention-to-treat princi-
le. The rates of end points were estimated with the use of
he Kaplan-Meier method, and the differences between
roups were estimated with the use of the log-rank test.
vent-free survival from MACE, TLR, and the composite
f death and MI occurring during the 5-year follow-up were
nalyzed using the Kaplan-Meier method. Differences be-
ween the event-free survival curves for the 2 groups were
ompared with the use of the log-rank test. A 2-sided
value 0.05 was considered statistically significant. All
tatistical analyses were performed using SAS statistical
oftware (SAS Institute, Cary, North Carolina).
esults
he baseline clinical characteristics of the RAVEL trial
opulation have been described in detail previously (1,5).
xcept for a significantly higher percentage of men in the
roup treated with BMS, the 2 study groups were similar
ith respect to all demographic and disease-related charac-eristics examined. The flow of patients through the trial is Thown in Figure 1. At 5 years, 14 patients had died and 4
atients were lost to follow-up in the SES-treated group,
nd 8 patients had died and 9 were lost to follow-up in the
MS-treated group. Among 106 SES and 110 BMS
ecipients who were not confirmed to have died, complete
atasets were available at 1,825 days in 98 patients treated
ith SES (92.5%) and 98 patients assigned to BMS
89.1%). The cumulative numbers and percentages of pa-
ients who experienced MACE or underwent TVR through
he 5-year follow-up are listed in hierarchical and nonhier-
rchical orders in Table 1. A significant difference (p 
.03) persisted in rate of MACE in favor of the SES-treated
roup, mostly attributable to a lower number of repeat TLR.
he 5-year actuarial survival rates for freedom from death
nd MI (Fig. 2) in patients assigned to SES versus patients
ssigned to BMS were similar. In contrast, significant
ifferences were observed in the MACE- (Fig. 3) and
Figure 1 Flow of Patients Through the Trial
LTF  lost to follow-up.LR-free (Fig. 4) survivals. Specifically, the 1-, 3-, and
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5-Year Outcomes in RAVEL October 2, 2007:1299–304-year survival rates free from TLR were, respectively,
9.2%, 93.8%, and 89.7% in the SES group versus 75.9%,
5.0%, and 74.0% in the BMS group (p 0.001; log-rank).
tent thrombosis. According to the per-protocol defini-
ions, 1 late thrombosis occurred at 1,217 days in a SES
ecipient (Table 2). After readjudication of the events
ccording to the ARC definitions, a single definite, very
ate stent thrombosis (0.8%) was observed in each study
roup, 2 versus 3 definite or probable thromboses were
bserved in the SES versus BMS groups, respectively,
nd a total of 4 thromboses of any kind (3.3%) was
bserved in the SES-treated group, versus 8 thromboses
f any kind (6.8%) in the BMS-treated-group, a nonsig-
ificant difference (Table 2).
eaths during follow-up. The RAVEL trial protocol did
ot distinguish between cardiac and noncardiac deaths. At
he end of 5 years, 14 patients assigned to SES (12.1%)
ersus 8 patients (7.1%) in the control group had died (p 
.20). The ages and diagnoses at the time of death for the
Figure 2 Survival Free From Death or MI
The sirolimus-eluting stent group is represented by a red line and the control
group by a blue line. Error bars indicate  1.5 standard error. MI  myocardial
infarction.
umulative Incidence of MACE Observed Upo 5 Years in 120 SES Versus 118 BMS Recipients
Table 1 Cumulative Incidence of MACE Observed Upto 5 Years in 120 SES Versus 118 BMS Recipients
SES BMS p Value
Hierarchical ranking
Death 14 (12.1) 8 (7.1) 0.20
Nonfatal myocardial infarction 8 (7.3) 4 (3.5) —
Target lesion revascularization
Surgical 3 (2.7) 2 (1.8) —
Percutaneous 5 (4.7) 27 (23.2) —
All MACE 30 (25.8) 41 (35.2) 0.03
Nonhierarchical ranking
Death 14 (12.1) 8 (7.1) 0.20
Myocardial infarction 10 (8.9) 8 (6.9) 0.65
Target lesion revascularization 11 (10.3) 30 (26.0) 0.001
Surgical 4 (3.6) 2 (1.8) 0.41
Percutaneous 8 (7.5) 28 (24.2) 0.001
Target vessel revascularization* 3 (2.7) 3 (2.6) 0.98
alues indicate numbers (%) of patients; p values were determined by the log-rank test. Rates of
dverse events were estimated by the Kaplan-Meier method. *Not involving the target lesion.
BMS  bare-metal stent; MACE  major adverse cardiac events (any death, myocardial
nfarction, or target lesion revascularization); SES  sirolimus-eluting stent.4 patients who died in the group assigned to SES and the
patients assigned to BMS are listed in Table 3.
iscussion
ain study findings. The main impetus for pursuing a
-year follow-up in this trial was the importance of
onfirming a durable antirestenotic effect of SES. When
AVEL was designed, observations in animal models
uggested that, instead of being effectively suppressed,
estenosis might merely have been delayed by sirolimus
lution (8). The observation, in this double-blind, random-
zed trial, of a statistically significant difference in rates of
ACE between SES and BMS, mostly attributable to a
ower TLR rate, persisting up to 5 years, confirms the
bsence of a “catch-up” effect and the durability of the
reatment effect observed in the “First-in-Man” study by
ousa et al. (9). Likewise, a significant difference in MACE
ate persisted at 5 years between the 2 small study groups,
ostly attributable to the higher TLR rate among the BMS
han the SES recipients.
Since the introduction of SES in clinical practice,
ther drug-eluting coronary stents have been developed
nd found to have antirestenotic effects (10 –13). The
AVEL study, however, has been the longest ongoing
Figure 3 Survival Free From MACE
The sirolimus-eluting stent group is represented by a red line and the control
group by a blue line. Error bars indicate  1.5 standard error. MACE  major
adverse cardiac events.
Figure 4 Survival Free From TLR
The sirolimus-eluting stent group is represented by a red line and the control
group by a blue line. Error bars indicate  1.5 standard error. TLR  target
lesion revascularization.
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October 2, 2007:1299–304 5-Year Outcomes in RAVELontrolled clinical trial. Although it was not designed
riginally to examine long-term clinical outcomes, its
-year results do not suggest that the beneficial antirest-
notic effects of SES were negated by short- or long-term
dverse clinical events. In particular, the difference be-
ween the study groups in rates of death and MI, up to 5
ears, was not significant.
In recent months, authors of meta-analyses or clinical
tudies have suggested that important safety concerns might
e associated with drug-eluting stents, an excess of death,
nd stent thrombosis in particular. As a result, a team of
xperts as well as scientific societies have more accurately
nd comprehensively redefined stent thrombosis (ARC
efinitions). Therefore, this report presents the stent throm-
osis rates calculated according to the per-protocol as well as
he ARC definitions. It is noteworthy that, as defined by the
rotocol and up to 5 years of follow-up, a single stent
hrombosis occurred in an SES recipient. Because it oc-
urred past the 3-year follow-up, this event did not appear
n prior publications of the RAVEL results. According to
tent Thromboses Adjudicated Per Protocol and According to the A
Table 2 Stent Thromboses Adjudicated Per Protocol and Accor
SES, n (%)
Acute Subacute Late
Per-protocol definitions 0 0 1
All per protocol 1
ARC definitions
Definite 0 0 0
Probable 0 0 0
Possible 0 0 0
Definite  probable 0 0 0
Any 0 0 0
All ARC 4 (3.3)
etween-groups differences are not significant.
ARC  Academic Research Consortium; NA  not applicable; other abbreviations as in Table 1
Deaths During Follow-Up in Each Study Group
Table 3 Deaths During Follow-Up in Each St
SES
Diagnosis Age (yrs) P
Oro-pharyngeal cancer 80
Sudden death 79
Intestinal cancer 66
Internal hemorrhage 79
Heart failure 71
Stroke 78
Pulmonary embolism 71
Heart failure 72
Cerebral hemorrhage 70
Subarachnoidal hemorrhage 57
Pancreatic cancer 78
Heart failure 74
Prostate cancer 69
Respiratory failure 76*Circumstances at time of death unclear.
Abbreviations as in Table 1.he ARC definitions, the stent thrombosis rate was low in
oth groups and not higher in the SES than in the BMS
roup, by any definition. This observation is particularly
mportant since the 2-month course of antiplatelet therapy
as the shortest administered among all trials of drug-
luting stents. These reassuring results must, however, be
nterpreted with caution because: 1) the study was not
esigned or powered to compare rates of infrequent adverse
linical events; and 2) the lesions treated in this study were
enerally low risk.
tudy limitations. The main limitation of this analysis out
o 5 years is the sample size and small number of events,
uch that it was not powered to detect statistically signifi-
ant between-group differences in rates of rare adverse
linical events, such as death, MI, or stent thrombosis.
onclusions
his trial demonstrates that the initial clinical benefit
onferred by SES is sustained at 5 years, as shown by a
efinitions in Each Study Group
to the ARC Definitions in Each Study Group
BMS, n (%)
y Late Acute Subacute Late Very Late
NA 0 0 0 NA
0
(0.8) 0 0 0 1 (0.8)
(0.8) 0 0 2 (1.7) 0
(1.7) 0 0 1 (0.8) 4 (3.4)
(1.7) 0 0 2 (1.7) 1 (0.8)
(3.3) 0 0 3 (2.5) 5 (4.2)
8 (6.8)
roup
BMS
# Diagnosis Age (yrs)
Perforated gastric ulcer 57
Sudden death 74
Cardiac death* 85
Cardiac death* 62
Sudden death 73
Gastric hemorrhage 72
Sudden death 75
Acute myocardial infarction 52RC D
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5-Year Outcomes in RAVEL October 2, 2007:1299–304ignificantly lower rate of TLR. Although there was no
pparent adverse effect associated with the use of SES, this
afety issue needs to be further evaluated in larger random-
zed trials and meta-analyses with a larger number of clinical
vents.
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